Eli Lilly and Company
LLY
$1288.30
+0.50%
Eli Lilly and Company is a global pharmaceutical manufacturer whose portfolio spans cardiometabolic health (Mounjaro, Zepbound, Trulicity, Jardiance, Humalog/Humulin), oncology (Verzenio, Jaypirca), immunology (Taltz, Olumiant), and neuroscience, with roughly 50,000 employees and a listing dating back to 1970. Lilly has evolved from a diversified legacy drugmaker into the dominant platform in the GLP-1 incretin class, and its tirzepatide franchise has made it the largest healthcare company by market capitalization and the reference standard against which obesity competitors such as Novo Nordisk, Viking Therapeutics, and Amgen are measured. The current investor debate centers on whether the incretin growth runway — management has guided toward up to $87 billion in 2026 revenue — can be sustained against intensifying competition (Novo's CagriSema and oral Wegovy, Viking's VK2735), looming patent-cliff questions, pricing and policy pressure, and the capital intensity of manufacturing buildouts. Sentiment has been further complicated by a hot-inflation print reviving rate-hike risk that pressures high-multiple growth names, even as Lilly's relative strength versus the S&P 500 remains decisively positive.…
LLY
Eli Lilly and Company
$1288.30
Related headlines
Investment Opinion: Should I buy LLY Today?
Rating: Hold. The core thesis is that Eli Lilly is a high-quality growth compounder with dominant GLP-1 franchise economics, but the current price of $1,273.46 already reflects much of the near-term optimism, with the average analyst target of $1,331.55 implying only +4.6% upside. The consensus recommendation of "buy" (mean 1.61) and recent reiterations from major banks support the quality of the franchise, but the risk/reward at current levels is more balanced than the consensus rating alone implies, especially given the wide target range of $930 to $1,600.
Supporting evidence includes: (1) revenue growth of 47.67% YoY in Q2 2026, with no deceleration in the sequential cadence; (2) operating margin expansion to 54.22% from 45.13%, demonstrating operating leverage; (3) a PEG ratio of 0.48, which frames the 46.58x trailing PE as reasonable relative to growth; (4) TTM free cash flow of $20.05B, providing ample capital flexibility; and (5) a low beta of 0.453, which supports risk-adjusted position sizing. However, the stock trades at a ~100%+ premium to the drug manufacturing sector on PE, and the 0.56% dividend yield offers no valuation support.
The biggest risks that could invalidate the thesis are: (1) competitive disruption from Novo's CagriSema or oral Wegovy, or Viking's VK2735, which could erode Lilly's incretin market share; (2) margin compression from obesity-market pricing pressure or policy headwinds; and (3) a de-rating of high-multiple growth stocks if inflation remains sticky and the Fed hikes rates. This Hold would upgrade to Buy if the stock pulls back to the $1,100–$1,150 support zone (implying ~20x forward PE) or if competitive threats prove overblown. It would downgrade to Sell if revenue growth decelerates below 30% YoY or if operating margins fall below 45%. Net-net, the stock is fairly valued to slightly overvalued relative to its history and peers, and investors should wait for a better entry point.
Sign up to view all
LLY 12-Month Price Forecast
The forward-looking view is balanced: Lilly's growth trajectory remains exceptional, but the stock's valuation already discounts much of the near-term optimism. The base case (55% probability) sees the stock trading in the $1,300–$1,400 range, roughly in line with the analyst average target, as earnings growth drives the multiple down to ~25x forward PE. The bull case (25%) requires sustained 40%+ growth and pipeline success, while the bear case (20%) hinges on competitive disruption and margin compression. I would upgrade to bullish if the stock pulls back to the $1,100–$1,150 support zone (implying ~20x forward PE) or if competitive threats prove overblown. I would downgrade to bearish if revenue growth decelerates below 30% YoY or if operating margins fall below 45%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Eli Lilly and Company's 12-month outlook, with a consensus price target around $1333.72 and implied upside of +3.5% versus the current price.
Average Target
$1333.72
0 analysts
Implied Upside
+3.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$930 - $1600
Analyst target range
Coverage is deep and overwhelmingly bullish: 30 analysts cover LLY with a consensus recommendation of "buy" and a mean rating of 1.61 (where 1.0 is a strong buy), and the average target price of $1,331.55 implies roughly +4.6% upside from the $1,273.46 current price. The consensus leans clearly bullish, and the recent institutional tape reinforces it — JP Morgan reiterated Overweight on September 28, TD Cowen and Guggenheim reiterated Buy in mid-September, and Truist, Cantor Fitzgerald, Wells Fargo, Citigroup, Bernstein, and UBS all maintained Buy/Outperform/Overweight ratings between July and August. The lone dissenter is HSBC at Reduce (reiterated September 10), a reminder that valuation and GLP-1 competition are the principal bear arguments.
The target range of $930 to $1,600 is wide — a 72% spread from low to high — signaling meaningful dispersion in assumptions about the incretin franchise's durability. The $1,600 high target implies roughly 25.6% upside and likely assumes sustained 40%+ revenue growth toward the $87 billion 2026 guide, multiple expansion on pipeline optionality (oral GLP-1, Alzheimer's, oncology), and successful defense against Novo, Viking, and Amgen. The $930 low target implies about 27% downside and prices in margin compression from obesity-market pricing pressure, share loss to CagriSema or oral Wegovy, and policy/IRA-style reimbursement headwinds. The absence of any recent downgrades — every action in the dataset is a reiteration — suggests strong conviction in the franchise, though the wide spread and the stock's proximity to its 52-week high mean the risk/reward at current levels is more balanced than the consensus "buy" rating alone implies.
Bulls vs Bears: LLY Investment Factors
The bull case currently has stronger evidence, anchored by exceptional revenue growth of 47.7% YoY, expanding operating margins at 54.22%, and a PEG of 0.48 that frames the 46.58x trailing PE as reasonable relative to growth. Analyst consensus is overwhelmingly positive with a mean rating of 1.61 and average target of $1,331.55, and the stock's low beta of 0.453 and $20.05B TTM free cash flow add defensive qualities. However, the bear case is not without merit: the premium valuation leaves little room for error, and intensifying competition from Novo's CagriSema, oral Wegovy, and Viking's VK2735 threatens the incretin franchise's durability. The single most important tension is whether Lilly can sustain 40%+ revenue growth toward its $87B 2026 guide while defending pricing power against emerging competitors—if growth decelerates or margins compress, the premium multiple could de-rate sharply.
Bullish
- Revenue growth accelerating at 47.7% YoY: Q2 2026 revenue reached $22.97B, up 47.67% from $15.56B in Q2 2025, following +55.5% in Q1 2026 and +42.6% in Q4 2025. The sequential cadence from $17.60B to $19.29B to $19.80B to $22.97B shows no deceleration, and consensus forward revenue of $134.4B implies the growth engine keeps compounding.
- Operating leverage driving margin expansion: Operating margin expanded to 54.22% in Q2 2026 from 45.13% a year earlier, while gross margin rose to 85.78% from 84.27%. Net income of $7.095B on a 30.88% net margin demonstrates that revenue is outgrowing opex, a hallmark of scalable platform economics.
- PEG of 0.48 signals growth at reasonable price: Despite a trailing PE of 46.58x, the forward PE of 26.97x and PEG of 0.48 suggest the stock is cheap relative to its earnings growth rate. Consensus EPS of $67.55 versus trailing EPS implies earnings are expected to roughly double, compressing the multiple by 42%.
- Strong analyst consensus with 30 analysts at Buy: The mean recommendation of 1.61 (where 1.0 is strong buy) and average target of $1,331.55 imply +4.6% upside, with a high target of $1,600 (+25.6%). Recent reiterations from JPMorgan, TD Cowen, Guggenheim, Truist, and UBS reinforce conviction, with only HSBC at Reduce.
Bearish
- Premium valuation leaves little room for error: At 46.58x trailing PE and 14.81x PS, LLY trades at roughly a 100%+ premium to the Drug Manufacturers-General industry's high-teens-to-low-20s earnings multiple. The 36.37x price-to-book is extreme given the thin equity base, and the 0.56% dividend yield offers no valuation support.
- Intensifying GLP-1 competition: Novo Nordisk's CagriSema delivered 25% weight loss in women in Phase 3, and oral Wegovy shows real-world weight loss after switching from injections. Viking Therapeutics raised $575M to fund Phase 3 trials for VK2735, and Amgen is also developing obesity assets, threatening Lilly's incretin dominance.
- Thin FCF yield and high cash-flow multiple: FCF yield is only ~2.1% on the $965B market cap, and the 57.4x price-to-cash-flow ratio shows the market is paying dearly for cash generation. Any slowdown in cash conversion or increased capex for manufacturing buildouts could compress this multiple.
- Quarterly earnings noise from other expenses: Q2 2026 net other expenses of $3.21B (versus $0.93B in Q1) dragged pre-tax income to $9.247B, highlighting how IPR&D charges and mark-to-market items can create volatility. This noise complicates earnings predictability despite strong operating trends.
LLY Technical Analysis
LLY is in a sustained, powerful uptrend: shares are up 55.10% over the past year versus just 13.13% for SPY, a relative-strength spread of 41.97 percentage points, and the stock has gained 44.06% over six months against SPY's 6.45%. At $1,273.46, the stock sits at roughly 90.7% of its 52-week range of $809.63–$1,321.21, having pulled back about 3.6% from the high — positioning that signals strong momentum but also proximity to overhead supply and some overextension risk after a near-vertical run. The 23.31% maximum drawdown over the period shows the stock is not immune to sharp air pockets despite the secular uptrend.
Short-term momentum is re-accelerating: the stock is up 10.64% over the past month versus a 1.02% decline for SPY (relative strength of +11.66 points), and up 6.47% over three months against SPY's 2.85%. This is a notable acceleration from the 6.47% three-month pace, implying most of the quarterly gain was earned in the last four weeks, and the 17.87% YTD advance confirms the trend is intact rather than a dead-cat bounce. The one blemish is the most recent session, a 2.54% decline from the $1,306.69 prior close on volume of roughly 2.27 million shares, suggesting profit-taking at the highs rather than a trend break; RSI is not provided in the dataset, so overbought/oversold conditions cannot be quantified directly.
Key resistance sits at the 52-week high of $1,321.21, with the recent $1,306.69 close marking the immediate battleground; a clean breakout above $1,321 would confirm the uptrend and likely trigger momentum-chasing flows, while failure opens a retest of the $1,200–$1,250 shelf that has repeatedly acted as support since August. Downside support anchors at the 52-week low of $809.63, roughly 36% below current levels, with intermediate support near the $1,100–$1,150 zone where the stock consolidated in September. The beta of 0.453 is unusually low for a high-growth name — roughly 55% less volatile than SPY on a measured basis — which supports larger position sizing on a risk-adjusted basis, though the 23.31% max drawdown and 3.01 short ratio (about three days of average volume to cover shorts) argue for disciplined stop placement.
Beta
0.45
0.45x market volatility
Max Drawdown
-23.3%
Largest decline past year
52-Week Range
$810-$1321
Price range past year
Annual Return
+57.1%
Cumulative gain past year
| Period | LLY Return | S&P 500 |
|---|---|---|
| 1m | +8.7% | +0.9% |
| 3m | +11.5% | +4.1% |
| 6m | +33.7% | +7.2% |
| 1y | +57.1% | +12.4% |
| ytd | +19.2% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LLY Fundamental Analysis
Revenue growth is exceptional and accelerating: Q2 2026 revenue reached $22.974 billion, up 47.67% year over year from $15.558 billion in Q2 2025, following $19.799 billion in Q1 2026 (+55.5% YoY versus $12.729 billion) and $19.292 billion in Q4 2025 (+42.6% YoY versus $13.533 billion). The sequential cadence — $17.60B (Q3 2025) → $19.29B → $19.80B → $22.97B — shows no deceleration, and the segment mix is overwhelmingly driven by Cardiometabolic Health at $18.353 billion, dwarfing Oncology ($2.570 billion), Immunology ($1.417 billion), and Neuroscience ($0.429 billion). Consensus estimates of $134.4 billion in forward revenue (range $125.7B–$142.8B) imply the growth engine is expected to keep compounding, which is the core of the bull case.
Profitability is elite and improving: Q2 2026 net income was $7.095 billion on a 30.88% net margin, with gross margin at 85.78% (up from 84.27% in Q2 2025 and 81.93% in Q1 2026) and operating margin at 54.22% — a striking expansion from 45.13% a year earlier, driven by operating leverage as revenue outgrew opex. The TTM net margin of 31.67% and operating margin of 45.56% are well above big-pharma norms in the high-20s to low-30s, reflecting tirzepatide's pricing power and manufacturing scale; R&D of $3.819 billion (16.6% of revenue) remains heavy but is comfortably absorbed. The one caveat is the $3.21 billion in net other expenses in Q2 (versus $0.93 billion in Q1), which dragged pre-tax income to $9.247 billion and shows how IPR&D charges and mark-to-market items can create quarterly noise.
Balance-sheet health is solid but leveraged: debt-to-equity stands at 1.60, the current ratio at 1.58, and ROE at an extraordinary 77.78% (ROA 20.36%), though the equity base is thin relative to assets. Free cash flow is robust at $20.05 billion TTM, with Q2 2026 FCF of $7.757 billion on $10.69 billion of operating cash flow against $2.933 billion of capex, and the company returned capital via $1.546 billion of dividends and $1.601 billion of buybacks while repaying $11.577 billion of debt and spending $8.747 billion on acquisitions. The FCF yield is thin at roughly 2.1% on the $965 billion market cap, and the 57.4x price-to-cash-flow ratio shows the market is paying dearly for that cash generation — but with interest coverage above 36x and $8.95 billion of cash, liquidity risk is low.
Quarterly Revenue
$23.0B
2026-06
Revenue YoY Growth
+47.7%
YoY Comparison
Gross Margin
85.8%
Latest Quarter
Free Cash Flow
$20.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LLY Overvalued?
Because net income is positive ($7.095 billion in Q2 2026), the PE ratio is the primary metric: LLY trades at 46.58x trailing earnings but only 26.97x forward earnings, a 42% compression that implies the market expects earnings to roughly double — consistent with consensus EPS of $67.55 versus the trailing figure. The PEG ratio of 0.48 is the standout data point, suggesting the stock is cheap relative to its growth rate, though the trailing PE of 46.6x is rich in absolute terms and the 15.20x EV/Sales and 31.57x EV/EBITDA multiples confirm a premium is being paid for the franchise.
Against the Drug Manufacturers–General industry, LLY's 46.58x trailing PE and 14.81x PS represent a substantial premium to the sector's typical high-teens-to-low-20s earnings multiple — roughly a 100%+ premium on PE — while the 36.37x price-to-book is extreme given the thin equity base. That premium is defensible on growth (47.67% revenue growth versus mid-single-digit sector norms), margins (85.78% gross, 54.22% operating), and the PEG of 0.48, but it leaves little room for execution error; the 0.56% dividend yield offers no valuation support.
Historically, LLY's PE has ranged from roughly 27.8x (Q1 2026) to 205x (Q3 2024, distorted by a depressed earnings base), with the current 46.58x sitting in the middle-to-upper portion of that band and well above the 36.2x–37.7x levels seen in late 2025 and Q2 2026. The PS ratio of 14.81x is actually near the low end of its multi-year range (which peaked above 78x in early 2024), reflecting revenue catching up to the multiple — a constructive signal that the valuation is being earned rather than merely expanded. Net-net, the stock is priced for optimistic but not unrealistic expectations, with the forward PE of 27x doing most of the work in the bull case.
PE
46.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 28x~76x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
31.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the company's leveraged balance sheet and dependence on continued growth to justify its valuation. Debt-to-equity stands at 1.60, and while interest coverage above 36x and $8.95B of cash mitigate liquidity risk, the thin equity base (ROE of 77.78%) amplifies financial fragility. The FCF yield of ~2.1% on a $965B market cap means the stock is priced for perfection; any slowdown in cash generation—whether from increased capex for manufacturing buildouts or margin pressure—could trigger a sharp re-rating. Additionally, quarterly earnings are subject to noise from other expenses, as seen in Q2 2026's $3.21B net other expenses versus $0.93B in Q1, which dragged pre-tax income to $9.247B and highlights earnings volatility.
Market and competitive risks are significant given the stock's premium valuation and the rapidly evolving obesity market. At 46.58x trailing PE and 14.81x PS, LLY trades at roughly a 100%+ premium to the drug manufacturing sector, leaving little room for execution error. Beta of 0.453 suggests low market correlation, but the stock is not immune to sector rotation or macro headwinds—the recent hot inflation print (3.7%) reviving Fed hike risk pressures high-multiple growth names. Competitive threats are mounting: Novo's CagriSema delivered 25% weight loss in Phase 3, oral Wegovy shows real-world efficacy, and Viking's VK2735 is advancing with a $575M raise. These developments could erode Lilly's incretin market share and pricing power, while policy risks such as IRA-style reimbursement headwinds add further uncertainty.
The worst-case scenario would involve a combination of GLP-1 market share loss to competitors, margin compression from pricing pressure, and a broader de-rating of high-multiple growth stocks due to rising rates. In this scenario, the stock could retest its 52-week low of $809.63, representing a 36% decline from the current price of $1,273.46. The analyst low target of $930 implies a 27% downside, while the 23.31% maximum drawdown over the past year shows the stock's vulnerability to sharp air pockets. A realistic downside scenario could see shares fall to the $930–$1,000 range (-22% to -27%) if growth decelerates and the forward PE compresses to 20x on lower earnings expectations.
FAQ
The key risks are: (1) competitive disruption—Novo's CagriSema delivered 25% weight loss in Phase 3, and Viking's VK2735 is advancing, which could erode Lilly's GLP-1 market share; (2) valuation compression—at 46.58x trailing PE, any slowdown in growth or rise in rates could compress the multiple; (3) policy and pricing pressure—IRA-style reimbursement headwinds could squeeze margins; and (4) financial leverage—debt-to-equity of 1.60 and a thin equity base (ROE 77.78%) amplify downside in a downturn. The most severe risk is competitive disruption, as it would directly impact revenue and margins.
Our 12-month forecast has three scenarios: bull case (25% probability) targets $1,450–$1,600, assuming sustained 40%+ growth and pipeline success; base case (55%) targets $1,300–$1,400, in line with the analyst average of $1,331.55, assuming 30–35% growth and stable margins; bear case (20%) targets $930–$1,000, assuming competitive disruption and margin compression. The base case is most likely, driven by earnings growth that compresses the forward PE to ~25x. Key catalysts include Q3 earnings, competitive data readouts, and Fed policy.
LLY is fairly valued to slightly overvalued. The trailing PE of 46.58x is roughly double the drug manufacturing sector's high-teens-to-low-20s multiple, and the PS of 14.81x and EV/EBITDA of 31.57x confirm a premium. However, the forward PE of 26.97x and PEG of 0.48 suggest the market is paying a fair price for growth. The stock's PS ratio is near the low end of its multi-year range (which peaked above 78x in early 2024), indicating revenue is catching up to the multiple. The market expects Lilly to sustain 30%+ earnings growth, and any shortfall would likely trigger a de-rating.
LLY is a high-quality growth stock, but at $1,273.46 it offers limited near-term upside. The average analyst target of $1,331.55 implies only +4.6% upside, and the stock trades at a premium 46.58x trailing PE. However, the PEG of 0.48 and forward PE of 26.97x suggest the valuation is reasonable relative to growth. The biggest downside risk is competitive disruption from Novo's CagriSema or Viking's VK2735, which could compress margins and the multiple. For long-term investors with a 3–5 year horizon, LLY is a good buy on pullbacks to the $1,100–$1,150 support zone; for short-term traders, the risk/reward is less favorable given the proximity to the 52-week high.
LLY is best suited for long-term investment. Its growth stage (47.7% revenue growth), low beta (0.453), and robust free cash flow ($20.05B TTM) support a buy-and-hold strategy, but the stock's 23.31% max drawdown and premium valuation make it unsuitable for short-term trading. The dividend yield is low (0.56%), so returns depend on capital appreciation. We recommend a minimum holding period of 3–5 years to ride out volatility and benefit from the GLP-1 growth runway. Short-term traders should wait for a pullback to the $1,100–$1,150 support zone or a breakout above $1,321.